Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
May 04 2023 - 4:06PM
Business Wire
Omeros Corporation (NASDAQ: OMER), today announced that the
company will issue its first quarter financial results for the
period ended March 31, 2023, on Tuesday, May 9, 2023, after the
market closes. Omeros management will host a conference call and
webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time) to discuss the financial results as well as recent
developments and highlights.
Conference Call Details
To access the live conference call via phone, please dial (800)
715-9871 from the United States and Canada or (646) 307-1963
internationally and ask to be placed into the Omeros earnings call.
Please dial in approximately 10 minutes prior to the start of the
call. A telephone replay will be available for one week following
the call and may be accessed by dialing (800) 770-2030 from the
United States or Canada or (609) 800-9909 internationally. The
replay access code is 8266699.
For online access to the live or subsequently archived webcast
of the conference call, go to Omeros’ website at
https://investor.omeros.com/upcoming-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy (TA-TMA).
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome.
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing across multiple clinical programs for alternative
pathway-related diseases, including paroxysmal nocturnal
hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more
information about Omeros and its programs, visit
www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230504006068/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2024 to May 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From May 2023 to May 2024